Abuse Liability of Hydrocodone Combination Products

Published Online: Tuesday, January 21, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, argues that studies comparing the abuse liability of hydrocodone combination products with that of other opioids have produced conflicting results.
 
This is the sixth in a series of videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
New coalition will focus on research and education to combat the abuse and misuse of stimulant medications on college campuses.
The FDA today approved AstraZeneca’s naloxegol (Movantik) treatment for opioid-induced constipation in adults with chronic noncancer pain.
The My GI Health tool tracks symptoms of gastroesophageal reflux disease over time, helping clinicians save time and improve patient care.
The Drug Enforcement Administration recently announced that all hydrocodone products will have a Cll status effective October 6, 2014.
Latest Issues
$auto_registration$